PMID- 34121322
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20220317
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
VI  - 68
IP  - 10
DP  - 2021 Oct
TI  - Race as a factor in donor selection and survival of children with hematologic 
      malignancies undergoing hematopoietic stem cell transplant in Florida.
PG  - e29180
LID - 10.1002/pbc.29180 [doi]
AB  - BACKGROUND: Previous studies have explored posthematopoietic cell transplant 
      (HCT) outcomes by race in adults; however, pediatric data addressing this topic 
      are scarce. PROCEDURE: This retrospective registry study included 238 White (W) 
      and 57 Black (B) children with hematologic malignancies (HM) receiving first 
      allogeneic HCT between 2010 and 2019 at one of the five Florida pediatric HCT 
      centers. RESULTS: We found no differences between W and B children in transplant 
      characteristics, other than donor type. There was a significant difference in use 
      of human leukocyte antigen (HLA)-mismatched donors (HLA-MMD) (53% W, 71% B, 
      p = .01). When comparing HLA-MMD use to fully HLA-matched donors, B had relative 
      risk (RR) of 1.47 (95% CI 0.7-3) of receiving a mismatched unrelated donor 
      (MMUD), RR of 2.34 (95% CI 1.2-4.4) of receiving a mismatched related donor 
      (MMRD), and RR of 1.9 (95% CI 0.99-3.6) of receiving a mismatched cord blood 
      donor (MMCBD) HCT, respectively. There was no significant difference in the 
      incidence of aGVHD (48% W, 35% B), p = .1, or cGVHD (19% W, 28% B, p = .1), or 
      primary cause of death. Overall 24-month survival was 61% (95% CI 55%-68%) for W, 
      and 60% (95% CI 48-75) for B children, log-rank p = .7. While HLA matching 
      improved survival in W children, the number of B children receiving HLA-matched 
      HCT was too small to identify the impact of HLA matching on survival. 
      CONCLUSIONS: In this contemporary cohort of children with HM, we found that B 
      children were more likely to receive HLA-MMD transplants, but this did not 
      adversely affect survival or GVHD rates.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Horn, Biljana
AU  - Horn B
AUID- ORCID: 0000-0002-1030-5946
AD  - University of Florida, Gainesville, Florida, USA.
FAU - Lamba, Nikhil
AU  - Lamba N
AD  - University of Florida, Gainesville, Florida, USA.
FAU - Chellapandian, Deepak
AU  - Chellapandian D
AUID- ORCID: 0000-0003-3518-9790
AD  - Center for Cell and Gene Therapy for Nonmalignant Conditions, Blood and Marrow 
      Transplant Program, Cancer & Blood Disorders Institute, Johns Hopkins All 
      Children's Hospital, St. Petersburg, Florida, USA.
FAU - Sunkersett, Gauri
AU  - Sunkersett G
AD  - Center for Cell and Gene Therapy for Nonmalignant Conditions, Blood and Marrow 
      Transplant Program, Cancer & Blood Disorders Institute, Johns Hopkins All 
      Children's Hospital, St. Petersburg, Florida, USA.
FAU - Silva, Jorge Galvez
AU  - Silva JG
AUID- ORCID: 0000-0003-3548-7720
AD  - Nicklaus Children's Hospital, Miami, Florida, USA.
FAU - Ziga, Edward
AU  - Ziga E
AD  - Pediatric Hematology and Oncology, University of Miami School of Medicine, Miami, 
      Florida, USA.
FAU - Alperstein, Warren
AU  - Alperstein W
AD  - Pediatric Hematology and Oncology, University of Miami School of Medicine, Miami, 
      Florida, USA.
FAU - Joyce, Michael
AU  - Joyce M
AD  - Nemours Children's Clinic and Wolfson Children's Hospital, Jacksonville, Florida, 
      USA.
FAU - Castillo, Paul
AU  - Castillo P
AUID- ORCID: 0000-0002-2813-1729
AD  - University of Florida, Gainesville, Florida, USA.
FAU - Fort, John
AU  - Fort J
AD  - University of Florida, Gainesville, Florida, USA.
FAU - Zhao, Jing
AU  - Zhao J
AUID- ORCID: 0000-0002-6005-644X
AD  - University of Florida, Gainesville, Florida, USA.
FAU - Oshrine, Benjamin
AU  - Oshrine B
AUID- ORCID: 0000-0002-2836-2244
AD  - Center for Cell and Gene Therapy for Nonmalignant Conditions, Blood and Marrow 
      Transplant Program, Cancer & Blood Disorders Institute, Johns Hopkins All 
      Children's Hospital, St. Petersburg, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210614
PL  - United States
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Child
MH  - *Donor Selection
MH  - Florida/epidemiology
MH  - *Graft vs Host Disease/epidemiology/etiology
MH  - HLA Antigens
MH  - *Hematologic Neoplasms/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Race Factors
MH  - Retrospective Studies
MH  - Unrelated Donors
OTO - NOTNLM
OT  - Florida consortium
OT  - malignant disorders
OT  - pediatric HCT
OT  - race disparities
EDAT- 2021/06/15 06:00
MHDA- 2022/03/18 06:00
CRDT- 2021/06/14 07:08
PHST- 2021/05/12 00:00 [revised]
PHST- 2021/04/03 00:00 [received]
PHST- 2021/05/25 00:00 [accepted]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2021/06/14 07:08 [entrez]
AID - 10.1002/pbc.29180 [doi]
PST - ppublish
SO  - Pediatr Blood Cancer. 2021 Oct;68(10):e29180. doi: 10.1002/pbc.29180. Epub 2021 
      Jun 14.